(DAPT) in patients treated with Firehawk stents was non-inferior to 12 months of DAPT for the primary composite event of all-cause death, myocardial infarction, cerebrovascular accident and major ...

FDA approved the Agent drug-coated balloon (DCB) for coronary in-stent restenosis, making this the first DCB to make it to the U.S. market, manufacturer Boston Scientific announced. In people with ...

Despite getting even more new data this April supporting the practice of using ticagrelor monotherapy as soon as 1 month after PCI for ACS, many cardiologists seem wary about dropping aspirin so ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Despite no slam-dunk evidence supporting the use of guided dual antiplatelet therapy (DAPT) strategies, either with platelet function or genotype testing, a new review paper argues that there’s still ...

MADRID -- Dual antiplatelet therapy (DAPT) didn't improve outcomes after coronary artery bypass grafting (CABG) for an acute coronary syndrome (ACS) but did increase risks, the TACSI randomized trial ...

Among low-risk patients with acute MI who underwent early complete revascularization and received one month of dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy was noninferior to ...